This segment focuses on the research, development, and commercialization of novel targeted solutions for cancer. Merrimack's R&D activities include preclinical studies, clinical trials, and biomarker analysis to identify patients who may benefit from their therapies. The company utilizes various technologies, including monoclonal antibodies and nanoliposomal formulations, to develop treatments. The primary therapeutic area is oncology, with a focus on improving patient outcomes in various cancer types. Merrimack's market positioning is as a clinical-stage biopharmaceutical company, and its competitive advantage lies in its targeted approach to cancer treatment. Future opportunities include expanding its pipeline and securing regulatory approvals for its product candidates. This segment involves clinical trials and regulatory compliance to ensure patient safety and efficacy. Partnerships and collaborations are essential for advancing research and development efforts.